



## **Technical Report No. 84**

# Integrating Data Integrity Requirements into Manufacturing & Packaging Operations

# **Integrating Data Integrity Requirements into Manufacturing & Packaging Operations**

---

## **Authors**

---

**Els Poff**, Merck (Chair)

**James Curry**, PhD, Teva Pharmaceuticals

**John Grealis**, PhD, Novartis

**Anne Pericone**, Johnson & Johnson

**Susan Schniepp**, Regulatory Compliance Associates Inc.

**Nader Shafiei**, PhD, Sanofi

**Ronald Tetzlaff**, PhD, Parexel Consulting

**Anthony Warchut**, AC Warchut GMP Consulting

## **Contributors**

---

**Jeffrey Broadfoot**, Emergent BioSolutions, Inc.

**Derek Glover**, Mylan

**Maryann Gribbin**, Faith & Royale Consultants

**Tina Morris**, PhD, American Association of Pharmaceutical Scientists

**Rebecca Parrilla**, U.S. Food and Drug Administration

**Carmelo Rosa**, PsyD, U.S. Food and Drug Administration

**Anil Sawant**, PhD, Merck

**Christopher Smalley**, PhD, ValSource, LLC

# **Integrating Data Integrity Requirements into Manufacturing & Packaging Operations**

**Technical Report No. 84**

ISBN: 978-1-945584-19-0

© 2020 Parenteral Drug Association, Inc.

All rights reserved.



# Table of Contents

<b>1.0 INTRODUCTION AND SCOPE</b> .....	<b>1</b>	4.5 Data Process Flow Maps .....	19
1.1 Purpose.....	1	<b>5.0 DATA INTEGRITY CONTROLS</b> .....	<b>21</b>
1.2 Scope.....	2	5.1 Potential Differentiation of Controls .....	22
<b>2.0 GLOSSARY AND ABBREVIATIONS</b> .....	<b>2</b>	5.2 Methodology Used to Determine Differentiated Controls .....	23
2.1 Abbreviations .....	5	5.3 Areas of Differentiated Data Integrity Controls ...	25
<b>3.0 DATA INTEGRITY TRENDS AT INTERNATIONAL DRUG MANUFACTURERS</b> .....	<b>6</b>	<b>6.0 CONTROLS FOR BIG DATA AS IT RELATES TO DATA INTEGRITY</b> .....	<b>38</b>
3.1 Historical Perspective .....	6	<b>7.0 REFERENCES</b> .....	<b>39</b>
3.2 Regulatory Guidance.....	10	<b>8.0 APPENDIX I: EXAMPLES — HOW TO USE THE 9-BOX VULNERABILITY GRID</b> .....	<b>40</b>
3.3 Industry Best Practices .....	10	8.1 API Process Examples .....	40
<b>4.0 QUALITY RISK MANAGEMENT APPLIED TO DATA INTEGRITY</b> .....	<b>11</b>	8.2 Finished Dosage Form Examples .....	46
4.1 Considerations in Assessing Risk .....	11	8.3 Sterility Assurance Examples.....	50
4.2 Data Integrity Risk Management.....	13	8.4 Tablet Packaging Process Examples.....	54
4.3 Data Vulnerability (9-Box).....	15	8.5 References for Appendix I.....	57
4.4 Using the Data Vulnerability Grid .....	17		

## FIGURES AND TABLES INDEX

<b>Figure 3.1.1-1</b>	FDA Warning Letters—DI Issues Related to Production Activities by Country of Inspected Location .....	<b>Figure 5.2-1</b>	Methodology Used to Determine Differentiated Controls .....
	7		23
<b>Figure 3.1.1-2</b>	Incidence of Warning Letters Citing Production Activities by Product Type (API vs Finished Pharmaceuticals) .....	<b>Table 5.2-1</b>	Categories Where Different Levels of Data Integrity Controls are Acceptable based on Criticality.....
	8		24
<b>Figure 3.1.2-1</b>	EU Non-Compliance Reports—DI.....	<b>Table 5.3.1-1</b>	Data Integrity Control Grid for Storage of and Access to Completed and Archived Paper Records .....
	8		26
<b>Table 3.1.3-1</b>	Examples of Data Integrity Issues in Production Operations cited by FDA and EU .....	<b>Table 5.3.2-1</b>	Data Integrity Control Grid for Issuance and Reconciliation of Paper Records.....
	9		27
<b>Table 4.1.1-1</b>	Human Factors Matrix .....	<b>Table 5.3.3.1-1</b>	Data Integrity Control Grid for Data Accuracy when Manually Recording without a Controlled Second Format .....
	12		28
<b>Figure 4.2-1</b>	Data Integrity Risk Management Model.....	<b>Table 5.3.3.2-1</b>	Data Integrity Control Grid for Data Accuracy when Transcribing Manually Recorded Data into an Electronic System .....
	14		29
<b>Table 4.2.1-1</b>	Classification of Data Criticality .....	<b>Table 5.2.3.3-1</b>	Data Integrity Control Grid for True Copy (Paper to Electronic) .....
	15		30
<b>Table 4.2.2-1</b>	Data Control Levels.....	<b>Table 5.3.4-1</b>	Data Integrity Control Grid for Access Controls for Electronic Systems .....
	15		31
<b>Table 4.3-1</b>	Data Vulnerability Grid (9-Box) – Example for Data Management Technology Controls .....	<b>Table 5.3.5.1-1</b>	ATRA Final Score and Frequency Review .....
	16		33
<b>Table 4.4-1</b>	Potential Areas of Data Integrity Vulnerability.....	<b>Table 5.3.5.2-1</b>	Example of How ATRA Tool is Used to Score a Filter Integrity Tester .....
	18		35
<b>Figure 4.5.1-1</b>	Case 1: Granulation Operation (Paper-Based Manual Process without Automated Alerts) .....		
	21		
<b>Figure 4.5.1-2</b>	Case 2: Granulation Operation (PLC-Controlled Process with Automated Alerts).....		
	21		

<b>Table 5.3.6-1</b>	Data Integrity Control Grid for Data Backup for System with Limited Storage Capacity.....37	<b>Table 8.2-3</b>	Example 6: Low Criticality – Humidity Monitoring During Sieving of a Drug Substance.....49
<b>Table 5.3.7.1-1</b>	Data Integrity Control Grid for Data Export for Generation of Reports and Records.....37	<b>Figure 8.3-1</b>	Simplified Illustration of Aseptic Filling Process.....50
<b>Table 5.3.7.2-1</b>	Data Integrity Control Grid for Data Transfer and Migration Between Electronic Systems.....38	<b>Table 8.3-1</b>	Example 7: High Criticality – Filter Integrity Testing at the Point of Fill (Post-Use) .....51
<b>Table 8.1-1</b>	Example 1: High Criticality API Reaction Controls Impurity Level .....42	<b>Table 8.3-2</b>	Example 8: Medium Criticality – Filter Integrity Testing at the Point of Fill (Pre-Use–Post-Sterilization).....52
<b>Table 8.1-2</b>	Example 2: Medium Criticality – Drying of API (LOD not a CQA).....43	<b>Table 8.3-3</b>	Example 9: Low Criticality – Filter Identity Verification at the Point of Fill (Pre-Use Pre-Sterilization) .....53
<b>Table 8.1-3</b>	Example 3: Low Criticality – Small Molecule API Batch-to-Batch Cleaning of Equipment within a Campaign .....45	<b>Figure 8.4-1</b>	Overview of the Packaging Process ...54
<b>Table 8.2-1</b>	Example 4: High Criticality – Humidity Monitoring During Sieving of a Drug Substance.....47	<b>Table 8.4-1</b>	Example 10: High & Medium Criticality – Tablet Packaging .....55
<b>Table 8.2-2</b>	Example 5: Medium Criticality – Humidity Monitoring During Sieving of a Drug Substance .....48		



Bethesda Towers  
4350 East West Highway  
Suite 600  
Bethesda, MD 20814 USA  
Tel: +1 (301) 656-5900  
Fax: +1 (301) 986-0296  
E-mail: [info@pda.org](mailto:info@pda.org)  
Web site: [www.pda.org](http://www.pda.org)